Aminoglycosides
High-yield Verified · Jul 2026Prototype: gentamicin
Gentamicin and relatives — bactericidal protein-synthesis inhibitors with a narrow safety margin. Watch for -micin.
How it works in the body
The system involved, what goes wrong, and how the drug and body interact.
01 Attacking the bacterial ribosome
Where penicillins and cephalosporins wreck the bacterial cell wall, aminoglycosides attack the bacterium’s protein factory — the ribosome. They bind the 30S ribosomal subunit and cause it to misread the genetic code, producing garbled, non-functional proteins. Because the damage is lethal, aminoglycosides are bactericidal (they kill), reserved mainly for serious Gram-negative infections and often combined with a cell-wall agent for synergy.
Their killing is concentration-dependent: a high peak relative to the bug’s susceptibility kills best, and they keep working after the level falls (a "post-antibiotic effect"). This is why modern dosing often uses a large once-daily dose — maximize the peak, then let the level trough low to protect the kidney.
02 The two toxicities that define the class
The same drug that saves the patient can injure two organs. Nephrotoxicity: aminoglycosides accumulate in the kidney’s proximal tubule cells and can cause acute kidney injury — usually reversible if caught early. Ototoxicity: they accumulate in the inner ear and damage the cochlea (hearing loss) and vestibular apparatus (dizziness, balance loss) — and this damage is often permanent.
Both toxicities rise when the drug lingers — high trough levels, prolonged courses, dehydration, existing kidney disease, and other nephro-/oto-toxic drugs (loop diuretics, vancomycin). That is the whole rationale for therapeutic drug monitoring: aim for a high peak (to kill) and a low trough (to protect the organs).
Drug names
Indications
- Serious Gram-negative infections (sepsis, complicated UTI, intra-abdominal, pneumonia)
- Synergy with a cell-wall agent for Gram-positive endocarditis
- Inhaled tobramycin for cystic-fibrosis Pseudomonas; topical/ophthalmic use
Mechanism of action
Bind the 30S bacterial ribosomal subunit, causing mRNA misreading and production of defective proteins — bactericidal, concentration-dependent killing with a post-antibiotic effect. Active mainly against aerobic Gram-negative organisms.
Therapeutic effects — what you'll see working
Success is clearing a serious Gram-negative infection, judged clinically and by cultures — while therapeutic drug monitoring keeps the peak high enough to kill and the trough low enough to spare the kidney and ears.
- Bactericidal Gram-negative kill
- Rapidly kills aerobic Gram-negative bacteria; the high peak relative to the organism’s MIC predicts success.
- Synergy with cell-wall agents
- Paired with a beta-lactam or vancomycin, aminoglycosides penetrate better and enhance killing (e.g., in endocarditis).
Adverse effects
The adverse effects are the drug accumulating where it shouldn’t — the kidney, the inner ear, and (rarely) the neuromuscular junction — which is exactly what monitoring is designed to prevent.
Interactions
Contraindications
The contraindications are the patients in whom accumulation or neuromuscular effects are especially dangerous.
When to hold
Assess before giving — these findings mean hold the dose and act.
Labs & levels
Nursing considerations
The RN-specific layer — each action paired with the reason it matters.
Sources
- Aminoglycosides — 30S mechanism, spectrum, nephro-/ototoxicity, monitoring — StatPearls (NCBI)
- Gentamicin — toxicity profile, therapeutic monitoring — StatPearls (NCBI)
- Gentamicin Sulfate Injection — boxed warning (neurotoxicity, neuromuscular blockade, fetal harm), FDA label — FDA / Pfizer label
Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.